• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    EyePoint, Inc. - Common Stock (NQ:EYPT)

    15.18 +2.24 (+17.27%)
    Streaming Delayed Price Updated: 11:08 AM EST, Feb 17, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 3,637,271
    Open 12.40
    Bid (Size) 15.12 (300)
    Ask (Size) 15.22 (400)
    Prev. Close 12.94
    Today's Range 12.34 - 15.69
    52wk Range 3.910 - 19.11
    Shares Outstanding 34,984,044
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data
    The multi-billion dollar wet Age-Related Macular Degeneration (wet AMD) market is standing on the precipice of a transformative shift. Today, February 16, 2026, Ocular Therapeutix (NASDAQ: OCUL) is in... 
    Via MarketMinute
    News headline image
    The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market
    The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year... 
    Via MarketMinute
    Topics Artificial Intelligence ETFs Initial Public Offering

    Performance

    YTD
    -13.2%
    -13.2%
    1 Month
    -2.3%
    -2.3%
    3 Month
    +15.5%
    +15.5%
    6 Month
    +33.9%
    +33.9%
    1 Year
    +132.0%
    +132.0%

    More News

    Read More
    News headline image
    Earnings Scheduled For November 5, 2025 ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For August 6, 2025 ↗
    Via Benzinga
    News headline image
    Analyst Expectations For EyePoint Pharmaceuticals's Future ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For May 7, 2025 ↗
    Via Benzinga
    News headline image
    A Peek at EyePoint Pharmaceuticals's Future Earnings ↗
    Via Benzinga
    News headline image
    Small-Cap Renaissance: Russell 2000 Scales New Heights While Big Tech Stumbles
    Via MarketMinute
    Topics Artificial Intelligence Economy Intellectual Property
    News headline image
    The Great Rotation: Small Caps Lead the Charge as 2026 Trading Opens
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    Demystifying EyePoint Pharmaceuticals: Insights From 4 Analyst Reviews ↗
    Via Benzinga
    News headline image
    The Small-Cap Renaissance: Why 2026 is the Year of the Russell 2000 and XSU
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    The 2026 Horizon: Technical Breakouts Signal a Sustained Bull Run in AI and Energy
    Via MarketMinute
    Topics Artificial Intelligence Economy Intellectual Property
    News headline image
    Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    EyePoint (EYPT) Q3 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) Shares Drop on Q3 Earnings and Revenue Miss ↗
    Via Chartmill
    Topics Earnings
    News headline image
    12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
    Via Benzinga
    News headline image
    EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study ↗
    Via Benzinga
    News headline image
    EyePoint (EYPT) Q2 Revenue Drops 44% ↗
    Via The Motley Fool
    News headline image
    EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) Q2 2025 Earnings Miss Estimates as Shares Drop 4.5% Pre-Market ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Forecasting The Future: 4 Analyst Projections For EyePoint Pharmaceuticals ↗
    Via Benzinga
    News headline image
    Breakout Momentum Plays You May Not Know About
    Via MarketBeat
    News headline image
    Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday ↗
    Via Benzinga
    News headline image
    Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    10 Health Care Stocks Whale Activity In Today's Session ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For March 5, 2025 ↗
    Via Benzinga

    Frequently Asked Questions

    Is EyePoint, Inc. - Common Stock publicly traded?
    Yes, EyePoint, Inc. - Common Stock is publicly traded.
    What exchange does EyePoint, Inc. - Common Stock trade on?
    EyePoint, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for EyePoint, Inc. - Common Stock?
    The ticker symbol for EyePoint, Inc. - Common Stock is EYPT on the Nasdaq Stock Market
    What is the current price of EyePoint, Inc. - Common Stock?
    The current price of EyePoint, Inc. - Common Stock is 15.18
    When was EyePoint, Inc. - Common Stock last traded?
    The last trade of EyePoint, Inc. - Common Stock was at 02/17/26 11:08 AM ET
    What is the market capitalization of EyePoint, Inc. - Common Stock?
    The market capitalization of EyePoint, Inc. - Common Stock is 530.88M
    How many shares of EyePoint, Inc. - Common Stock are outstanding?
    EyePoint, Inc. - Common Stock has 531M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.